Daiwa Securities Group’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $64K | Buy |
12,706
+2,883
| +29% | +$14.5K | ﹤0.01% | 1039 |
|
|
2025
Q1 | $52K | Sell |
9,823
-312
| -3% | -$1.65K | ﹤0.01% | 1018 |
|
|
2024
Q4 | $69K | Buy |
10,135
+2,235
| +28% | +$15.2K | ﹤0.01% | 1024 |
|
|
2024
Q3 | $52K | Buy |
7,900
+32
| +0.4% | +$211 | ﹤0.01% | 1065 |
|
|
2024
Q2 | $59K | Sell |
7,868
-3,214
| -29% | -$24.1K | ﹤0.01% | 1081 |
|
|
2024
Q1 | $110K | Sell |
11,082
-677
| -6% | -$6.72K | ﹤0.01% | 1039 |
|
|
2023
Q4 | $116K | Buy |
11,759
+11,028
| +1,509% | +$109K | ﹤0.01% | 993 |
|
|
2023
Q3 | $6K | Hold |
731
| – | – | ﹤0.01% | 1141 |
|
|
2023
Q2 | $5K | Sell |
731
-7,680
| -91% | -$52.5K | ﹤0.01% | 1177 |
|
|
2023
Q1 | $56K | Buy |
8,411
+1,508
| +22% | +$10K | ﹤0.01% | 1033 |
|
|
2022
Q4 | $53K | Buy |
6,903
+6,292
| +1,030% | +$48.3K | ﹤0.01% | 1027 |
|
|
2022
Q3 | $7K | Sell |
611
-11,584
| -95% | -$133K | ﹤0.01% | 1140 |
|
|
2022
Q2 | $99K | Buy |
12,195
+4,954
| +68% | +$40.2K | ﹤0.01% | 1021 |
|
|
2022
Q1 | $52K | Buy |
7,241
+2,127
| +42% | +$15.3K | ﹤0.01% | 1083 |
|
|
2021
Q4 | $88K | Buy |
+5,114
| New | +$88K | ﹤0.01% | 1025 |
|